Human Neural Stem Cell Therapy for Chronic Ischemic Stroke: Charting Progress from Laboratory to Patients

Area of Science:

• Neuroscience
• Regenerative Medicine
• Stem Cell Therapy

Background:

• Chronic stroke disability remains a significant unmet neurological need.
• Human neural stem cells (hNSCs) offer a potential therapeutic avenue for post-stroke recovery.
• ReNeuron is developing CTX0E03 (CTX), an hNSC therapy for chronic stroke.

Purpose of the Study:

• To review the development and clinical progress of ReNeuron's CTX hNSC therapy for chronic stroke.
• To highlight the manufacturing capabilities and mechanistic properties of CTX.
• To provide an outlook on the future clinical development of this stroke therapy.

Main Methods:

• Review of published Phase I trial data for safety and efficacy signals.
• Description of a single-arm Phase II multicenter trial in patients with upper-limb paresis.
• Explanation of the c-mycER^TAM technology for large-scale hNSC manufacturing under cGMP conditions.

Main Results:

• Phase I trial demonstrated no safety concerns and suggested promising efficacy.
• Phase II trial has completed recruitment, indicating progress in clinical evaluation.
• CTX possesses pro-angiogenic, pro-neurogenic, and immunomodulatory properties crucial for stroke recovery.

Conclusions:

• CTX cell therapy has advanced from laboratory research to clinical trials.
• Scalable manufacturing ensures supply for research, clinical development, and market needs.
• The therapy holds potential for addressing chronic disability after stroke, with ongoing late-stage clinical evaluation.